Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides
Naotake Tsuda
Department of Immunology, School of Medicine, Kurume University, Kurume 830-0011, Japan
Search for more papers by this authorKumiko Murayama
Cancer Vaccine Development Division, Research Center for Innovative Cancer Therapy, Kurume University, Kurume 830-0011, Japan
Search for more papers by this authorHyota Ishida
Department of Immunology, School of Medicine, Kurume University, Kurume 830-0011, Japan
Department of Orthopedic Surgery, School of Medicine, Kurume University, Kurume 830-0011, Japan
Search for more papers by this authorKazuko Matsunaga
Cancer Vaccine Development Division, Research Center for Innovative Cancer Therapy, Kurume University, Kurume 830-0011, Japan
Search for more papers by this authorSetsuro Komiya
Department of Orthopedic Surgery, School of Medicine, Kurume University, Kurume 830-0011, Japan
Search for more papers by this authorKyogo Itoh
Department of Immunology, School of Medicine, Kurume University, Kurume 830-0011, Japan
Cancer Vaccine Development Division, Research Center for Innovative Cancer Therapy, Kurume University, Kurume 830-0011, Japan
Search for more papers by this authorCorresponding Author
Akira Yamada
Department of Immunology, School of Medicine, Kurume University, Kurume 830-0011, Japan
Cancer Vaccine Development Division, Research Center for Innovative Cancer Therapy, Kurume University, Kurume 830-0011, Japan
Department of Immunology, School of Medicine, Kurume University, Kurume 830-0011, Japan, Tel.: +81-942-31-7744; fax: +81-942-31-7745Search for more papers by this authorNaotake Tsuda
Department of Immunology, School of Medicine, Kurume University, Kurume 830-0011, Japan
Search for more papers by this authorKumiko Murayama
Cancer Vaccine Development Division, Research Center for Innovative Cancer Therapy, Kurume University, Kurume 830-0011, Japan
Search for more papers by this authorHyota Ishida
Department of Immunology, School of Medicine, Kurume University, Kurume 830-0011, Japan
Department of Orthopedic Surgery, School of Medicine, Kurume University, Kurume 830-0011, Japan
Search for more papers by this authorKazuko Matsunaga
Cancer Vaccine Development Division, Research Center for Innovative Cancer Therapy, Kurume University, Kurume 830-0011, Japan
Search for more papers by this authorSetsuro Komiya
Department of Orthopedic Surgery, School of Medicine, Kurume University, Kurume 830-0011, Japan
Search for more papers by this authorKyogo Itoh
Department of Immunology, School of Medicine, Kurume University, Kurume 830-0011, Japan
Cancer Vaccine Development Division, Research Center for Innovative Cancer Therapy, Kurume University, Kurume 830-0011, Japan
Search for more papers by this authorCorresponding Author
Akira Yamada
Department of Immunology, School of Medicine, Kurume University, Kurume 830-0011, Japan
Cancer Vaccine Development Division, Research Center for Innovative Cancer Therapy, Kurume University, Kurume 830-0011, Japan
Department of Immunology, School of Medicine, Kurume University, Kurume 830-0011, Japan, Tel.: +81-942-31-7744; fax: +81-942-31-7745Search for more papers by this authorAbstract
We recently reported that a SART3 tumor-rejection antigen possessing tumor epitopes is capable of inducing HLA class I-restricted and tumor-specific cytotoxic T lymphocytes in cancer patients. We studied the expression of the SART3 protein in musculoskeletal tumors to find a molecule for potential use in tumor-specific immunotherapy. The SART3 was detected at protein levels in 100% of the osteosarcoma cell lines (n = 20), in 50% of the musculoskeletal tumor tissue specimens (n = 32), and at notable levels in 67% of osteosarcoma tissues (n = 9) and malignant fibrous histiocytosis tissues (n = 9), respectively. SART3-derived peptides at positions 109-118 and 315-323 induced HLA-A24-restricted tumor-specific cytoxic T lymphocytes from peripheral blood mononuclear cells of patients with osteosarcoma or malignant fibrous histiocytosis. These peptide-induced cytotoxic T lymphocytes recognized HLA-A24+ SART3+ osteosarcoma cells but not HLA-A24− or SART3− cells. These results suggest that the SART3 protein and its derived peptides could be molecules appropriate for use in specific immunotherapies for approximately 60% of HLA-A24+ patients with osteosarcoma or malignant fibrous histiocytosis. © 2001 Orthopaedic Research Society. Published by Elsevier Science Ltd. All rights reserved.
References
- 1 Gaugler B, Van den Eynde B, van der Bruggen P, Romero P, Gaforio JJ, De Plaen E, Lethe B, Brasseur F, Boon T. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J Exp Med 1994; 179: 921–30.
- 2 Gomi S, Nakao M, Niiya F, Imamura Y, Kawano K, Nishizaka S, Hayashi A, Sobao Y, Oizumi K, Itoh K. A cyclophilin B gene encodes antigenic peptides recognized by HLA-A24-restricted and tumor-specific CTLs. J Immunol 1999; 163: 4994–5004.
- 3 Goorin AM, Andersen JW. Experience with multi agent chemotherapy for osteosarcoma: improved outcome. Clin Orthop 1991; 270: 22–8.
- 4 Gu J, Shimba S, Nomura N, Reddy R. Isolation and characterization of a new 110 kDa human nuclear RNA-binding protein (p110nrb). Biochim Biophys Acta 1998; 1399: 1–9.
- 5 Harada K, Yamada A, Mine T, Kawagoe N, Takasu H, Itoh K. Mouse homologue of human SART3 gene encoding tumor rejection antigen. Jap J Cancer Res 2000; 91: 239–47.
- 6 Imanishi T, Akazawa T, Kimura A, Tokunaga K, Gojobori T. Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: K Tsuji, M Aizawa, T Sasazuki editors. HLA 1991, vol. 1, pp. 1065–1220. Oxford Scientific Publications; 1992.
- 7 Kang X, Kawakami Y, El-gamil M, Wang R, Sakaguchi K, Yannelli JR, Appella E, Rosenberg SA, Robbins PF. Identification of a tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J Immunol 1995; 155: 1343–8.
- 8 Kawakami Y, Eliyahu S, Sakaguchi K, Robbins PF, Rivoltini L, Yannelli JR, Appella E, Rosenberg SA. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994; 180: 347.
- 9 Kawakami Y, Eliyahu S, Delgado CH, Robbins PF, Rivoltini L, Topalian SL, Miki T, Rosenberg SA. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci, USA 1994; 9: 3515–19.
- 10 Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA. Recognition of multiple epitopes in the human melanoma antigen gp 100 by tumor-infiltrating T lymphocytes associated with in vitro tumor regression. J Innunol 1995; 154: 3961–8.
- 11
Kawamoto M,
Shochijo S,
Imai Y,
Imaizumi T,
Koga T,
Yanaga H,
Itoh K.
Expression of the SART-1 tumor rejection antigen in breast cancer.
Int J Cancer
1999;
80: 64–7.
10.1002/(SICI)1097-0215(19990105)80:1<64::AID-IJC13>3.0.CO;2-7 CAS PubMed Web of Science® Google Scholar
- 12
Kikuchi M,
Nakao M,
Inoue Y,
Matsunaga K,
Shichijo S,
Yanama H,
Itoh K.
Identification of a SART-1-derived peptide capable of Inducing the HLA-A24 restricted and tumor-specific cytotoxic T lymphocytes.
Int J Cancer
1999;
81: 459–66.
10.1002/(SICI)1097-0215(19990505)81:3<459::AID-IJC21>3.0.CO;2-6 CAS PubMed Web of Science® Google Scholar
- 13 Link MP, Goorin AM, Horowitz M, Meyer WH, Belasco J, Baker A, Ayala A, Shuster J. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity: update results of the mult-institutional study. Clin Orthop 1991; 270: 8–14.
- 14 Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, Cascinelli N, Bourlond A, Vanwijck R, Humblet Y, Canon JL, Laurent C, Naeyaert JM, Plagne R, Deramaeker R, Knuth A, Jager E, Brasseur F, Herman J, Coulie PG, Boon T. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer 1995; 63: 883–5.
- 15 Matsumoto H, Shichijyo S, Kawano K, Nishida T, Sakamoto M, Itoh K. Expression of the SART-1 antigen in uterine cancers. Jpn J Cancer Res 1999; 89: 1292–5.
- 16 Nakao M, Yamana H, Imai Y, Toh Y, Toh U, Kimura A, Yanoma S, Kakegawa T, Itoh K. HLA A2601-restricted CTLs recognize a peptide antigen expressed on squamaus cell carcinoma. Cancer Res 1995; 55: 4248–52.
- 17 Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, Burg G, Schadendorf D. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med 1998; 4: 328–32.
- 18 Robbins PF, El-Gamil M, Li YF, Kawakami Y, Loftus D, Appella E, Rosenberg SA. A mutated β-catenin gene encodes a melanoma- specific antigen recognized by tumor-infiltrated lymphocytes. J Exp Med 1996; 183: 1185–92.
- 19 Robbins PF, El-Gamil M, Li YF, Fitzgerald EB, Kawakami Y, Rosenberg SA. The intronic region of an incompletely spliced gp gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. J Immunol 1997; 159: 303–8.
- 20 Robbins PF, El-Gamil M, Li YF, Topalian SL, Rivoltini L, Sakaguchi K, Appella E, Rosenberg SA. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 1995; 154: 5944–50.
- 21
Rosen G,
Marcove R,
Caparros B,
Nirenberg A,
Kosloff C,
Huvos AG.
Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery.
Cancer
1979;
43: 2163–77.
10.1002/1097-0142(197906)43:6<2163::AID-CNCR2820430602>3.0.CO;2-S CAS PubMed Web of Science® Google Scholar
- 22 Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Restifo NP, Dudley ME, Schwarz SL, Spiess PJ, Wunderlich JR, Parkhurst MR, Kawakami Y, Seipp CA, Einhorn JH, White DE. Immunologic and therapeutic evaluation of a synthetic vaccine for the treatment of patients with metastatic melanoma. Nature Med 1998; 4: 321–7.
- 23 Seki N, Kamizono S, Yamada A, Higuchi T, Matsumoto H, Niiya F, Kimura A, Tsuchiya K, Suzuki R, Date Y, Tomita T, Itoh K, Ochi T. Polymorphisms in the 5′-flanking region of the tumor necrosis factor-α gene in patients with rheumatoid arthritis. Tissue Antigens 1999; 54: 194–7.
- 24 Shichijo S, Nakao M, Imai Y, Takasu H, Kawamoto M, Niiya F, Yang D, Toh Y, Yamana H, Itoh K. A gene encoding antigenic peptides of human squamous cell carcinoma recognized by cytotoxic T lymphocytes. J Exp Med 1998; 187: 277–88.
- 25 Sudo T, Kuramoto T, Komiya S, Inoue A, Itoh K. Expression of MAGE genes in osteosarcoma. J Orthop Res 1997; 15: 128–32.
- 26 Traversari C, van der Bruggen P, Luescher IF, Lurquin C, Chomez P, Van Pel A, De Plaen E, Amar-Costesec A, Boon T. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J Exp Med 1992; 176: 1453–7.
- 27 van der Bruggen P, Bastin J, Gajewski T, Coulie PG, Boel P, De Smet C, Traversari C, Townsend A, Boon T. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol 1994; 24: 3038–43.
- 28 van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643–7.
- 29 Yang D, Nakao M, Shichijo S, Sasatomi T, Takasu H, Matumoto H, Mori K, Hayashi A, Yamana H, Shirouzu K, Itoh K. A new gene coding for a protein prossesing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 1999; 59: 4056–63.
- 30 Ishida H, Komiya S, Inoue Y, Yutani S, Inoue A, Itoh K. Expression of the SART1 tumor-rejection antigen in human osteosarcomas. Int J Oncol 2000; 17: 29–32.
- 31 Ho M, Shichijo S, Miyagi Y, Kobayashi T, Tsuda N, Yamada A, Saito N, Itoh K. Identification of SART3-derived peptides capable in inducing HLA-A2-restricted and tumor-specific CTLs in cancer patients with different HLA-A2 subtypes. Int J Cancer 2000; 88: 633–9.
